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SUMMARY
Previous findings in our laboratory have
demonstrated that transplants of adrenal
medullary tissue into the spinal subarachnoid
space can alleviate pain, most likely via
sustained local release of pain-reducing
neuroactive substances from the transplanted
chromaffin cells. The success of this work in
animal models has led to preliminary clinical
trials with promising results. However, before
large-scale clinical studies are undertaken,
numerous issues should be resolved, many of
which can be readily addressed initially in the
laboratory. One of these is the amount of donor
adrenal medullary tissue necessary to produce
long-term antinociception. Although tissue from
two adrenal glands has generally been used, it is
unknown whether less would be equally
effective, or more could increase analgesic
potency. To address this, various amounts of
adrenal medullary tissue, ranging from one to
ten donor glands, were used. Results showed
lowered antinociceptive benefits when only one
adrenal medulla was used, but only small and
short-lived increases when donor material was
increased substantially. In addition, assays of
atecholamine and Met-enkephalin release in
the host spinal CSF revealed only slight further
increases following the transplantation of more
than 2-4 glands. These results indicate that a
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small amount of adrenal medullary tissue is
necessary and sufficient to produce sustained
antinociception, and suggest that higher
amounts may result in tolerance development or
feedback inhibition. Another important issue is
the ability to retain antinociceptive potency if
donor tissue is maintained in culture prior to
transplantation, since the coordination of donor
harvesting and recipient availability is often
difficult. To address this, donor adrenal
medullary tissue was maintained in explant
culture for various periods following dissection.
Results indicated that adrenal medullary tissue
can be maintained in culture for up to 30 days
prior to transplantation without decrement in
antinociceptive potency, and that a period of 7-
21 days results in improved graft viability.
Results of this study indicate that some of the
critical issues for successful neural trans-
plantation outcomes can be initially addressed in
pre-clinical studies.
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INTRODUCTION
Chromaffin cells in the adrenal medulla produce
and release several neuroaetive substances which
make them viable candidates as a graft source for
pain alleviation. In particular, these cells synthesize
and release opioid peptide products from the
proenkephalin precursor/2,12,13,23,30/, in addition
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to catecholamines. Notably, both opioid and
adrenergic agonists reduce nociception when
injected locally into the spinal subarachnoid space.
Furthermore, the co-administration of subeffective
doses of both types of agents appears to
synergistically produce potent analgesia, with
limited tolerance development /4,22,29,36/. Thus,
adrenal medullary transplants may provide an ideal
combination ofpain-reducing neuroactive agents for
the long-term alleviation of pain. Previous studies in
our laboratory have demonstrated that the trans-
plantation of adrenal medullary tissue into the spinal
subaraehnoid space of rats can reduce pain
symptoms in acute and chronic pain models
/10,18,20/. This is most likely due to the co-release
of both opioid peptides and catecholamines from
the transplanted cells since it can be blocked by
either opioid or (x-adrenergic antagonists /18,20/.
Furthermore, adrenal medullary transplants result in
elevated CSF levels of Met-enkephalin and
cateeholamines for at least 6 months following
transplantation/15,16/. The success ofthese studies
has led to limited clinical trials in cancer pain
patients with promising findings/19/.
Prior to attempting larger-scale clinical trials,
several basic issues need to be resolved. Many of
these can be addressed, at least initially, in the
laboratory. For example, the preparation of adrenal
medullary allogratt tissue for transplantation in
order to optimize pain-reducing capabilities, as well
as logistics, is critical to the success of this
approach. Previous studies in our laboratory have
utilized adrenal medullary tissue from two donor
glands. This reliably reduces pain sensitivity and
increases CSF levels of pain-reducing neuroactive
substances following transplantation into the host
spinal subarachnoid space. However, neither the
minimum nor optimum amount of donor tissue for
pain reduction has been determined. In addition, in
previous studies, adrenal medullary tissue has been
removed from donors and transplanted immediately
into the spinal subarachnoid space of host animals.
This procedure may be inconvenient for clinical
purposes, since it is otten difficult to coordinate
harvesting of donor tissue with timing for surgical
implantation. One approach to overcoming this
difficulty would be to maintain the donor tissue in
culture prior to transplantation. Another advantage
ofmaintaining tissue in explant culture is that it may
allow for recovery from anoxic trauma following
dissection. Thus, the goal ofthe present studies was
to assess optimal procedures to increase the
likelihood of successful pain reduction by adrenal
medullary allogratts. A preliminary account of these
results has been presented previously/27/.
MATERIALS AND METHODS
Animals
In all of the following studies, male Sprague-
Dawley rats (250-300 g) were used as both hosts
and donors. The rats were obtained from Sasco
Laboratories (WI) and housed in the animal care
facility at the University of Illinois at Chicago.
These procedures followed the guidelines for the
care and use of animals established by the Society
for Neuroscienee and the Animal Care Committee
at the University of Illinois at Chicago.
Preparation of transplant tissue
Donor adrenal medullary tissue was obtained
from adult rats and prepared for transplantation as
illustrated in Figure 1.The donors were anesthetized
with ether and killed by cervical dislocation. Their
adrenal glands were rapidly removed aseptically and
placed in ice cold Hanks’ buffer. Under a dissecting
microscope, adrenal cortical tissue was carefully
dissected from the medullary tissue. Adrenal
medullary tissue was cut into small pieces (0.5-1.0
cu.mm) and either placed in ice-cold Hanks’ buffer
for transplantation (within 30 min following
dissection; Fig. 1 at A), or placed in tissue culture
for various periods of time prior to transplantation
(Fig. 1 at B). The latter was done in order to assess
the consequences and limitations of maintaining the
tissue for various periods prior to transplantation.
For tissue culture, the adrenal medullary pieces
were washed in Locke’s buffer containing
kanamycin, penicillin-streptomycin, and fungizone
for 10 to 15 minutes, and placed in culture by
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Diagram of surgical implantation of rat adrenal medullary transplants (A) or adrenal medullary explants 03) into
the spinal cord subarachnoid space of rats (see text for details). AG: adrenal gland; K: kidney; AC: adrenal cortex;
AM: adrenal medulla.
seeding in small volumes of 1"1 DMEM:F12
medium containing 50% fetal bovine serum at 37C
and 5% CO. The low volume and high serum aid in
the initial attachment of the pieces to the 24-well
culture plates. The explanted adrenal medullae were
incubated at 37C and 5% CO for 2-3 hours before
more medium was added gradually over a 2-3 day
period until a final concentration of 5% FBS in 1"1
DMEM:F12 was reached. Explants were maintained
in tissue culture for 1, 3, 7, 10, 14, 21 and 30 days
until transplanted. When used for surgery, the
explants were washed and transferred in Hanks’
buffer until transplanted (within 30 min). Striated
muscle tissue from the same rat strain was used for
control graffing. The preparation of control tissue
for either immediate implantation or implantation
following culturing was the same as that for the
adrenal medullary tissue.
Surgical transplantation
arachnoid space of the rat
in the spinal sub-
Tissue for transplantation was introduced into
the spinal subarachnoid space of host animals using
aseptic surgical techniques (Fig. 1). Animals were
anesthetized with pentobarbital (30 mg/kg, i.p.,
supplemented as necessary). A laminectomy was
performed to expose a 3-4 mm segment of the
lumbar enlargement. Under a dissecting microscope,
a small slit was made in the dura and arachnoid
mater. In order to determine minimum and optimal
grat tissue amounts for reduction of pain, tissue
ranging from 1-10 adrenal medullae was used (see
Experimental Design). In control animals, equal
volumes of striated muscle were used. Graft tissues
were placed in the subarachnoid space and pushed
under the dura and arachnoid away from the slit to
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keep them in place. Following implantation, the
musculature was sutured with 3-0 silk, and the skin
was closed with wound clips.
Analgesiometric tests
Acute pain sensitivity in these studies was
assessed by use of the tail flick test, the paw pinch
test, and the hot plate test. The tail flick test/3/
measures a simple reflect to avoid a noxious thermal
stimulus. To determine response to the tail flick
test, a radiant heat stimulus was focused on the
blackened area of the dorsal surface of the rat’s tail
and the time interval between the onset of the
stimulus and the tail flick response was measured at
three regions of the tail, the average of which was
defined as the ’tail flick latency’. To prevent tissue
damage in the absence of a response, the stimulus
was terminated at 14 seconds and the tail flick
latency assigned a value of 14.
The paw pinch response is a reflexive response
to mechanical pressure, elicited by a commercially
available apparatus (Ugo-Basile) that applies
pressure at a constant increasing rate of 64 g/see.
The force was applied to the ventral surface ofboth
hind paws sequentially until the animal reacted with
a withdrawal response. The apparatus automatically
terminates at a scale reading of25 (= 1000 g).
The hot plate test /31/ is a more integrated
response to a contact thermal pain stimulus. The hot
plate response was determined by placing the rats
on a 55C copper plate enclosed in a plexiglass
cylinder. The interval between placement on the hot
plate and the response of licking the hind paws is
defined as the ’hot plate latency’. In the absence of a
response, the animals were removed after 40
seconds and assigned a hot plate latency of 40. In
studies where multiple repeated testing is required
(e.g. the explant study described below), the hot
plate test cannot be used, due to interference by
learning, which results in jumping immediately after
placement in the plexiglass cylinder.
Biochemical analysis
A spinal superfusion technique/15,16/was used
to measure the levels of catecholamines and opioid
peptides released imo the cerebrospinal fluid (CSF)
of animals with various amounts of adrenal
medullary or control transplants. To measure
release of these substances into spinal cord
superfusates, animals were anesthetized with
urethane (1200 mg/kg), fitted with a tracheal tube,
and placed in a stereotaxic instrument with the head
angled downward. An intrathecal catheter made of
PE10 tubing was threaded down the intrathecal
space of the rats via a small silt in the atlanto-
occipital membrane. The tip of the catheter lay at
the lumbar enlargement, where the transplant had
been previously placed. The rostral end of the
catheter was connected to the infusion end of a
push-pull pump. Saline containing bacitracin (30
lag/l) and bovine serum albumin (100 mg/1), to
inhibit peptidase activity and reduce non-specific
binding, respectively, was constantly infused at a
rate of0.1 ml per minute. Outflow was collected via
PE50 tubing placed over the opening in the dura.
Following a 30-45 minute superfusion period to
allow for stabilization of basal release, three 5 min
samples were collected sequentially. After collection
of the third sample, nicotine (0.1 mg/kg, s.c.) or
saline was injected, and an additional 5 min sample
was collected. The superfusate samples were
divided into two groups for enkephalin and
eateeholamine assays, respectively. The samples for
cateeholamine assays were collected into tubes
containing antioxidants (2.5 mg/ml L-eysteine, 0.5
mg/ml sodium metabisulfite, and 4.0 mg/ml EDTA).
All samples were frozen and lyophilized until
assayed.
Met-enkephalin release was assessed using
standard radioimmunoassay (RIA) techniques with
Met-enkephalin antiserum (Incstar, final dilution
1:6000). This antibody has been shown to cross-
react 2.8% with Leu-enkephalin, 0.1% with
endorphin, and <0.002% with substance P, 13-
endorphin, dynorphin 1-13, and t-neo-endorphin.
Prior to assay, samples were reconstituted in 0.2 N
HC1 and extracted on Sep-Pak preparatory
cartridges (Waters) to remove salts. Peptides were
eluted from the columns with 60% acetonitrile in
0.1% trifluoroacetic acid. Serially diluted Met-
enkephalin standards (Bachem) were used for
generation of the standard curve. The reaction was
stopped using IgGsorb (Enzyme Center; diluted
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1:40) and the bound fraction was pelleted for
counting. The sensitivity limit for this assay was
determined to be 0.5 pg of Met-enkephalin. Sample
concentrations were corrected for recovery of
authentic Met-enkephalin which was 95-99%.
Cateeholamine samples were resuspended in 0.4
N HCIO4, and extracted by alumina adsorption.
Standards containing authentic norepinephrine
(NE), epinephrine (EPI), and dopamine (DA) were
processed along with the CSF samples. Recoveries
for all three catecholamines were 70-90%.
Cateeholamines were quantified using reverse-phase
HPLC with electrochemical detection. The HPLC
mobile phase was 0.07 M NaHPO4, 0.2 mM octyl
sodium sulfate, 0.1 mM EDTA, 8% methanol, pH
4.8, and the flow rate over a Waters Resolve C18
column was set at 1.0 ml/min. Catecholamine
concentrations in the samples were calculated from
relative peak areas corrected for recovery using a
Waters Baseline 810 system. The lower detection
limits for the assay were 5-10 pg.
Morphologic analysis
At the termination of the studies, transplant
viability was analyzed morphologically using
immunocytoehemical techniques. The rats were
deeply anesthetized with pentobarbital (50 mg/kg,
i.p.), and perfused via the aorta with saline followed
by 4% paraformaldehyde in 0.1 M phosphate buffer.
Parts of the spinal cord containing the transplants
were dissected and placed in 20% sucrose in 0.1 M
phosphate buffer overnight at 4C for
eryoprotection. FiKeen micron sections were cut on
a cryostat (Hacker-Bright) and processed for
tyrosine hydroxylase (TI-I) immunoreactivity
(lncstar, diluted 1:500) with a rhodamine-linked
secondary antibody (Cappel, diluted 1:100). Pre-
immune serum was used on control sections. The
sections were coverslipped in Fluoromount, and
observed in a Zeiss Axiophot fluorescence
microscope. In some cases, to assess potential host
spinal compression, particularly following the
implantation of large volumes of tissue, spinal cord
tissue was embedded in Epon, and semi-thin
sections were stained with toluidine blue.
Experimental design
1. Minimum and optimal adrenal medullary tissue
forpain reduction
To determine the effective range of adrenal
medullary tissue necessary to produce analgesia,
animals were implanted with medullary tissue
dissected from 1, 2, 4, 6, 8, or 10 adrenal glands.
Six animals received each of the doses of adrenal
medullary implants. Control animals were
implanted with corresponding volumes of striated
muscle tissue (n 12, such that two animals
received graft volumes equal to each adrenal
medullary transplant group). Pain sensitivity was
assessed at 2, 4, 8, and 12 weeks following
transplantation. Baseline pain sensitivity and
response to nicotine stimulation (0.1 mg/kg, s.c.)
were determined at these time points, since previous
findings have indicated that this dose reliably
produces analgesia in animals with adrenal
medullary but not control transplants 116,18/.
Following termination of behavioral testing, CSF
samples were collected from the animals using
spinal superfusion as described above. Both basal
release and release following nicotine stimulation
(0.1 mg/kg, s.c.) were analyzed for catecholamines
and Met-enkephalin levels.
2. Adrenal medullary explants
In order to determine whether graft tissue can
be maintained in culture prior to transplantation,
animals were implanted with adrenal medullary
tissue either immediately (within 30 min) following
dissection from adrenal cortical tissue, or following
a period of 1, 3, 7, 10, 14, 21, or 30 days in culture
(n 9-10 animals per group). Animals received the
adrenal medullary tissue derived from two adrenal
glands, and control animals received equal volumes
of striated muscle maintained in parallel cultures.
Baseline nociceptive responses and responses to
nicotine stimulation (0.1 mg/kg, s.c.) were assessed
2, 4, 8, and 12 weeks following tissue implantation
into the spinal cord. At the end of behavioral
testing procedures, animals were perfused for
immunocytochemical analysis of the grafts as
described above.
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Statistical analysis
Statistical comparisons for overall significance
between treatment groups at each time point were
done using analysis of variance (ANOVA).
Multiple post-hoe analysis for comparisons between
individual treatment groups was done using the
Neuman-Keuls test/24/.
RESULTS
Minimum and optimal adrenal medullary tissue
for transplantation
In order to determine whether increasing the
amount of adrenal medullary tissue transplanted to
the spinal subarachnoid space can produce
increased antinociceptive potency, transplant tissue
amounts ranged from adrenal medullary tissue
derived from 1-10 adrenal glands. Since baseline
nociceptive responses were not altered in any of the
transplant groups, these were omitted for clarity of
presentation. These baseline nociceptive responses
as assessed by the three analgesiometdc tests were
comparable to those obtained in other studies in
intact, non-transplanted animals (e.g. see /70,
indicating that the surgical implantation procedures,
regardless of volume transplanted, produced no
significant alterations in baseline nociceptive
thresholds. In addition, no obvious signs of motor
impairment were observed in any of the animals in
response to transplantation.
Results of this study are shown in Figure 2.
Animals receiving control striated muscle
transplants were grouped together, since there were
no significant changes in pain responsiveness in
these animals following nicotine stimulation (P >
0.05). In contrast, in animals receiving any amount
of adrenal medullary tissue, even from only one
adrenal gland, significant antinociception following
nicotine was observed as assessed by the tail flick
test (Fig. 2A; P < 0.05). Statistically significant
antinociception was not produced by one adrenal
medullary transplant when assessed by the paw
pinch or hot plate tests (Fig. 2B and C; P > 0.05).
However, all other graft amounts, ranging from 2-
10 adrenal medullae, produced significant
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Effect oftransplants of 1 to 10 adrenal medullae or
control tissue in the spinal cord subaraclmoid
space of rats 2 min following nicotine injection
(0.1 mg/kg, s.c.). The ordinate is the threshold for
response to noxious stimuli as assessed by the tail
flick test (A), paw pinch test (B), and hot plate test
(C). Each point represents the mean +/- S.E.M..
The abscissa is months after traxmplantation.
Overall n 48 animals; overall F values for each
time point (df 6, 47; P < 0.01) 39.08, 43.44,
63.40, 75.42 (tail flick; 2, 4, 8, and 12 weeks,
respectively); 44.99, 52.55, 53.02, 22.58 (paw
pinch; 2, 4, 8, and 12 weeks, respectively); 14.72,
26.78. 14.84, 30.85 (hot plate; 2, 4, 8, and 12
weeks, respectively).
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antinociception with these tests (P < 0.05 compared
to control transplanted animals). In addition, in
general there appeared to be a trend towards
increasing antinociceptive potency with increasing
amounts of adrenal medullary tissue transplanted,
particularly at the earlier phases post-transplantation
(2-4 weeks). For example, significant improve-
ments in tail flick antinoeieeptive potency were
obtained when two or more glands were used
compared to one transplanted adrenal medulla (P <
0.05). In addition, increases to 6, 8, or 10 glands
produce greater antinoeieeption (P < 0.05). How-
ever, these differences were most pronounced in the
early post-transplantation period, and by 12 weeks
post-transplantation, while slight improvements in
antinoeieeptive potencies were still seen in animals
with larger gratt amounts, these were not
statistically significant (P > 0.05 between transplant
groups ranging from 2-10 glands) using the tail flick
test. Similar trends were obtained using the hot
plate and paw pinch tests, which revealed an initial
improved antinoeieeptive potency with increasing
transplant amounts. As with the tail flick test, this
tended towards equal potencies by 12 weeks post-
transplantation, with a slight, but statistically
insignificant increase in antinociception in animals
with larger graft amounts (P > 0.05 between all
adrenal medullary transplant groups).
Figure 3 shows the results of direct measure-
ments of eateeholamines and Met-enkephalin from
different amounts of adrenal medullary tissue in the
spinal CSF using the superfusion technique. The
mean basal release of NE in the spinal CSF was
signitieantly increased in animals with adrenal
medullary transplants compared to animals with
control transplants (Fig. 3A; P < 0.05). Basal NE
levels were increased greatly by the transplantation
oftwo adrenal medullae compared to one gland (P
< 0.05). While increasing amounts of adrenal
medullary tissue further increased basal CSF NE
levels, only 10 adrenal glands reached statistically
different levels. Basal levels of EPI were also
increased in adrenal medullary transplanted animals
compared to control transplanted animals (P < 0.05
for all adrenal medullary transplanted groups), with
further increases reaching statistical signitieance for
only the group receiving 10 adrenal medullae.
Similarly basal DA levels were slightly, but
significantly, increased in animals receiving 2-10
adrenal medullae (P < 0.05). Fig. 3B shows
catecholamine levels in spinal CSF samples
following systemic nicotine injection. Nicotine
injection had no effect on the CSF levels of NE,
EPI, or DA in control transplanted animals (P >
0.05 compared to basal levels). In contrast, NE and
EPI levels were increased by nicotine in all animals
with adrenal medullary transplants. In particular,
NE levels were consistently increased four- or five-
fold in animals with 2-10 transplanted adrenal
medullae. Nicotine-stimulated DA was also
apparent, but only in animals with larger amounts Of
adrenal medullary tissue transplanted (8-10 glands).
Stimulated release of NE in adrenal medullary
transplanted animals was increased in animals
receiving four compared to two adrenal medullae (P
< 0.05), but further increases were not apparent (P
> 0.05).
Met-enkephalin release in spinal superfusates is
shown in Fig. 3C. Mean basal levels of Met-
enkephalin release were higher in animals with
transplants of 4 to 10 adrenal medullae than those
of control animals or with transplants of one to two
adrenal medullae (P < 0.05). Nicotine produced
significant increases in Met-enkephalin release from
basal levels in animals with transplants oftwo to ten
adrenal medullae (P < 0.01), but not in animals with
transplants of either one adrenal medulla or control
muscle (P > 0.05). An intermediate amount of
adrenal medullary tissue (6 medullae) appeared to
release the highest levels of Met-enkephalin
following nicotine, with decrements when more
tissue was added, but the differences between 2 and
10 adrenal medullae were not statistically significant
(P > 0.05).
The appearance of host spinal cord from an
animal receiving 10 adrenal medullae is shown in
Figure 4. Fig. 4A is a low magnification showing a
portion of the transplanted adrenal medullary tissue
lying at the dorsal surface of the host spinal cord.
The transplanted tissue appears to fill the available
subarachnoid space beneath the dura mater, and
surrounds the host dorsal spinal vein. There is no
apparent damage or compression to host spinal cord
parenchyma. At higher magnification in Fig. 4B, a
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Release of catecholamines and Mct-enkcphalin in
spinal supetes of animals with adrenal
medullary or control transplants. A. Basal
catecholamine release in the spinal CSF of
animals with transplants of 1 to 10 adrenal
medullae or control striated muscle in the spinal
cord subaraclmoid space 3 months following
surgery. Bars represent the mean +/- S.E.M. levels
of norepincphrinc, epinephrine, and dopaminc per
5 rain sample collection interval. B. Nicotine
stimulated release of catecholamincs into spinal
cord supctcs in animals with transplants of 1
to 10 adrenal medullae or control tissue in the
spinal cord subarachnoid space. Bars represent
the mean +/- S.E.M. levels of norepincphrinc,
epinephrine, and dopaminc in the 5 min interval
following nicotine injection (0.1 mg/kg, s.c.). C.
Basal and nicotine-stimulated release of
Mct-cnkcphalin into spinal cord supcrfusatcs in
animals with transplants of 1 to 10 adrenal
medullae or control tissue. Spinal CSF samples
were collected before and 5 rain after nicotine
injection (0.1 mg/kg, s.c.). NE-BASAL basal
norepinephrine release; EPI-BASAL basal
epinephrine release; DA-BASAL basal
dopamine release; NE-NICOTINE nicotine-
stimulated norepinephrine release; EPI-
NICOTINE nicotine-stimulated epinephrine
release; DA-NICOTINE nicotine-stimulated
dopamine release; ENK-BASAL basal Met-
enkephalin release; ENK-NICOT1NE nicotine-
stimulated Met-enkephalin release; CON control
(striated muscle) transplants. Overall n 48
animals; overall F values for each release group
(dr 6, 47; P < 0.01) 17.87 (NE-BASAL); 19.87
(NE-NICOTINE); 33.46 (EPI-BASAL); 22.07
(EPI-NICOTINE); 22.39 (DA-BASAL); 8.09
(DA-NICOTINE); 5.22 (ENK-BASAL); 29.01
0NK-NICOTINE).
cluster of chromaiIin cells can be seen. These trans-
planted cells retain their in situ cuboidal
morphology, and are well vascularized. The
remainder of the transplanted tissue contains
elements of connective tissue including fibroblasts
and collagen.
Tissue culture maintenance of adrenal
medullary explants
The purpose of this series of studies was to
determine whether adrenal medullary tissue can be
maintained in explant culture over a period of time
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prior to transplantation without significant
decrement in viability or pain-reducing capabilities.
Figures 5 and 6 show antinociceptive responses
following transplantation of adrenal medullary
explants as assessed by the tail flick (Fig. 5) and
paw pinch (Fig. 6) tests. As assessed by the tail
flick test, nicotinic stimulation produced significant
antinoeieeption in animals with either direct adrenal
medullary transplantation, or transplantation of
adrenal medullary explants maintained in culture for
2 WKS AFTER TRANSPLANT 8 WKS AFTER TRANSPLANT
BASELINE NICOTINE BASELINE NICOTINE
el 12
-) 10
C
0 3 7 10 14 21 30 0 3 7 10 14 21 30
DAYS IN CULTURE DAYS IN CULTURE
4 WKS AFTER TRANSPLANT
12 WKS AFTER TRANSPLANT
BASELINE NICOTINE
BASELINE NICOTINE
Fig. 5:
DAYS IN CULTURE 0 3 7 10 14 21 30
DAYS IN CULTURE
F-ffccts ot’ cxp]anted adrcz medul]az7 tissue in the spinal cord subazacImoid space of mrs on pain sensitivity
assessed by the tail flick test. The abscissa shows the number of days explants were maintained in culture prior to
transplantation. The ordinate is the threshold for response to the noxious stimulus as determined by the test. The
solid bar in each pair is the baseline pain threshold. The cross-hatched bar in each pair is response 2 min
following nicotine injection (0.1 mg/kg, s.c.). The equivalent of medullary tissue dissected from two adrenal
glands was used in all animals. A, B, C, D: 2, 4, 8, and 12 weeks after transplantation, respectively. Overall n
78 animals; overall F values following nicotine for each time point (dr 7, 77) 1.71 (2 weeks); 1.96 (4 weeks);
2.23 (8 weeks); 2.10 (12 weeks). P > 0.05 for all groups, indicating that maintenance in tissue culture does not
result in significant decrement in antinociceptive potency.
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Effects of explanted adrenal medullary tissue in the spinal cord subaraclmoid space of rats on pain sensitivity
assessed by the paw pinch test. The abscissa shows the number of days explants were maintained in culture prior
to transplantation. The ordinate is the threshold for response to the noxious stimulus as determined by the test.
The solid bar in each pair is the baseline pain threshold. The second bar in each pair is the response 2 min
following nicotine injection (0.1 mg/kg, s.c.). The equivalent of medullary tissue dissected from two adrenal
glands was used in all animals. A, B, C, D: 2, 4, 8, and 12 weeks after transplantation, respectively. Overall n
78 animals; overall F values following nicotine for each time point (df 7, 77) 1.04 (2 weeks); 0.74 (4 weeks);
0.58 (8 weeks); 0.40 (12 weeks). P > 0.05 for all groups, indicating that maintenance in tissue culture does not
result in significant decrement in antinociceptive potency.
various time periods ranging from 1-30 days (P <
0.05). Similar to earlier findings, this dose of
nicotine produced no effect in animals with control
striated muscle transplants (P > 0.05, not shown).
The antinoeiceptive potency of the explants was
maintained without significant decrement from 2 to
4, 8, and 12 weeks post-transplantation (Fig. 5 A-
D; P > 0.05 between times after transplantation).
The results following maintenance in explant culture
revealed that there was no reduction in the potency
of adrenal medullary transplants whether they were
implanted immediately following dissection or kept
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in tissue culture for up to 30 days prior to
transplantation (P > 0.05 between transplant groups
at all time points). Findings using the paw pinch
test were virtually identical, showing no significant
decrements in antinoeiceptive potency of the
transplants over time, whether the medullary tissue
was transplanted immediately, or after 1-30 days in
culture (Fig. 6 A-D).
Following termination of behavioral testing,
animals receiving adrenal medullary transplants or
explants were perfused, and their spinal cords
processed for tyrosine hydroxylase (TH)
immunocytochemistry to assess chromaffin cell
viability (Fig. 7). Twelve weeks atter trans-
plantation, adrenal medullary tissue implanted
immediately after dissection contained numerous
TH-positive cells, as described in previous studies
(Fig. 7, Day 0). Transplants oftissues maimained in
culture for 1-3 days appeared to contain fewer, but
still numerous TH positive cells, possibly due to
transplantation in the early stages following
dissections. In contrast, transplants of tissues
maintained in culture for 7, 10, 14, 21 and 30 days
contained numerous TH positive cells, with the
greatest density between 7 and 21 days in culture.
These TH positive cells did not appear to sprout
processes and retained their in situ cuboidal
morphology. In addition, these grafts typically
remained in the spinal cord subarachnoid space and
did not integrate noticeably with the surrounding
host CNS parenchyma.
DISCUSSION
Previous findings in our laboratory have
demonstrated that adrenal medullary allografts in
the rat spinal subarachnoid space can reduce pain
sensitivity, most likely by providing a sustained and
renewable source of pain-reducing neuroactive
substances such as opioid peptides and
catecholamines /10,15,16,18,20/. The success of
these rodent studies has led to the initiation of
limited clinical trims in human cancer patients with
promising results/19/. However, before large-scale
clinical trials should be undertaken, especially in
light of the variable and often disappointing
outcomes in the clinical Parkinson’s disease
transplantation programs (see/6,7/), there are many
unknowns that could be readily addressed in the
laboratory. The goal of this work was to address
some ofthese issues and so lead to more consistent
and effective outcomes in future clinical trials.
One aspect of these studies was to determine
whether an optimal amount of adrenal medullary
tissue exists in order to produce reliable pain
reduction. Using behavioral antinociceptive assays,
results indicated that, while tissue from one adrenal
medulla can produce some antinocieeption, this can
be improved significantly by the transplantation of
tissue from two or more adrenal medullae. The
further inclusion of greater amounts of adrenal
medullary tissue appears to augment antinociceptive
potency in a correlative fashion, but these
differences are apparent primarily in the early post-
transplantation phases. At later periods, the
beneficial effects of larger amounts of adrenal
medullary tissue in the transplants, while not
completely eliminated, diminish to a large extent.
Thus, an intermediate amount of adrenal medullary
tissue (e.g. from 2 to 6 glands) seems to be
sufficient for maximally attainable antinociception
using this technique.
One possible explanation for the finding that
increasing graft tissue amounts does not result in
sustained improvements in antinocieeptive potency
is that the high levels of exposure to analgesic
agents released by the transplants results in the
development of host tolerance. In particular,
tolerance to opioids, resulting in diminished
antinociceptive potency is a well-documented result
of repeated or continual administration /1,14,25,
33,34/. Previous findings in our laboratory have
suggested that there is little tolerance development
in animals with transplants from two adrenal glands
/28/. However, exposure of the host spinal cord to
increased levels of these agents by greater amounts
of transplanted adrenal medullary tissue could result
in tolerance development. Similarly, exposure to
high levels of opioid peptides by transfected ART-20
cells, which produce both 13-endorphin and pro-
enkephalin products, produces rapid tolerance to
opioids atter transplantation in the spinal sub-
arachnoid space /32/. These results suggest the
interesting possibility that an optimal level of
adrenal medullary tissue for transplantation does not
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necessarily require large amounts of donor material,
which may, in fact, be detrimental due to host
tolerance development. Rather, subeffective levels
of synergistic pain-reducing neuroactive substances
provided by smaller amounts of adrenal medullary
tissue may be optimal. In support for this, the
synergistic antinociception provided by the co-
activation of spinal opioid and tz-adrenergic
receptors is well documented and, using sub-
effective levels of agents acting at both, may also
result in reduced tolerance development
/4,22,29,36/. Thus, the combination of neuroactive
substances produced by adrenal medullary
transplants may optimally produce co-activation of
opioid and ct-adrenergic receptors with subeffective
levels ofboth classes of agents.
One possible contradiction in the explanation
that tolerance development accounts for the failure
of increasing amounts of adrenal medullary tissue to
produce increased analgesia is that antinociceptive
effects are not completely eliminated in the presence
of high levels of graft tissue; rather these levels
produce antinoeiception similar to that of smaller
amounts of adrenal medullary transplants. In
addition, neurochemical assays suggest that
markedly increased levels of catecholamines and
opioid peptides are not produced by large amoums
of adrenal medullary tissue transplants. Thus,
tolerance development may be a factor in the
inability to increase antinociceptive potency, but
cannot completely account for the observed
findings. Another possibility is that there is poor
survival of adrenal medullary tissue in the spinal
subarachnoid space beyond an optimal level.
Alternatively, increased exposure of grafted cells to
their released products could result in feedback
inhibitory mechanisms resulting in lowered output
of neuroactive substances. Results from the
superfusion studies tend to support this to some
extent, revealing substantially increased
catecholamine and Met-enkephalin release when
transplant tissue is increased from one to two
glands, but only slight increases beyond that. This
is contrary to expected linearly-related increases in
neuroactive substances provided by increasing
numbers of transplanted chromaffin cells. In
support for this, continued exposure to both
catecholamines and opioid peptides has been shown
to reduce basal and nicotine-evoked secretion from
adrenal medullary cells in culture/5,9,11,21,26/.
Regardless of the mechanisms, results of the
first part of these studies indicate that small
quantities ofadrenal medullary tissue (e.g. from two
adrenal glands) are necessary and sufficient to
produce optimal CSF levels of pain-reducing
neuroactive substances for sustained anti-
nociception. In the second part of the study, the
potential for increasing usefulness of donor adrenal
medullary tissue by maintaining it in culture until
recipiem and graft availability can be coordinated,
was assessed. Results indicated that there was no
decrement in antinociceptive potency when the
adrenal medullary tissue was kept in culture for up
to 30 days. However, interestingly, immuno-
eytoehemical staining of TH indicated denser
distributions of TH positive cells in adrenal
medullary transplants maintained in culture for
longer periods (particularly 7 to 21 days) than those
placed in culture for shorter times. Although not
quantified, the density ofTH positive cells appeared
greater in transplants of these cultured adrenal
medullary explants than in those transplanted
immediately after dissection. These findings suggest
that there may be a recovery period following initial
trauma from dissection procedures. Similar findings
were reported for human adrenal medullary explants
/17/. Thus, to maximize chromatfin cell survival, it
may be advisable to maintain adrenal medullary
tissue in culture for several days, when it is not
feasible to transplant the tissue immediately.
Another possible advantage of maintenance in
explant culture for a period of time is that is may
allow for the migration of passenger leukocytes out
of the explanted tissue, reducing the potential
immunologic response when transplanted to an
allogeneic host. However, in this study, pain
thresholds assessed by analgesiometde tests were
not different, in spite of maintenance for various
periods in culture. Thus, regardless of apparent
increased ehromaffin cell viability in longer term
explants, sufficient numbers of chromaffin cells for
pain reduction apparently survive following shorter
times in culture.
In conclusion, results from this study suggest
that small amounts of donor adrenal medullary
tissue may be sufficient for producing long-lasting
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pain reduction when transplanted into the spinal
subarachnoid space. Furthermore, attempts to
improve antinociceptive potency by markedly
increasing adrenal medullary tissue may result in
supraoptimal delivery of pain-reducing neuro-active
substances, leading to host tolerance development
or feedback down-regulation in secretion from
transplanted cells. Results from this study also
indicate that rat adrenal medullary tissue can survive
and be transplanted without decrement in
antinoeieeptive potency following maintenance in
explant tissue culture for at least one month. One
of the problems with the use of human allografts is
the difficulty in coordinating organ donor
availability and recipient preparation. Findings of
the present study suggest that it may be possible, or
even preferable, to harvest and maintain viability of
donor adrenal tissue without immediate
implantation into the host. In summary, results of
this study indicate that some ofthe critical issues for
successful neural transplantation outcomes can be
initially addressed in pre-clinical studies.
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